Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Non-metastatic NSCLC and other thoracic malignancies

1237MO - SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial

Date

18 Sep 2020

Session

Mini Oral - Non-metastatic NSCLC and other thoracic malignancies

Presenters

Sacha Rothschild

Citation

Annals of Oncology (2020) 31 (suppl_4): S744-S753. 10.1016/annonc/annonc263

Authors

S.I. Rothschild1, A. Zippelius1, E.I. Eboulet2, S. Savic Prince3, D. Betticher4, A. Bettini4, M. Früh5, M. Joerger5, C. Britschgi6, S. Peters7, M.T. Mark8, A.F. Ochsenbein9, W. Janthur10, C. Waibel11, N. Mach12, M. Gonzalez13, P.R. Froesch14, G. Godar2, C. Rusterholz2, M. Pless15

Author affiliations

  • 1 Medical Oncology, University Hospital Basel, 4031 - Basel/CH
  • 2 Coordinating Center, SAKK, Bern/CH
  • 3 Pathology, Institute of Pathology-University Hospital Basel, 4031 - Basel/CH
  • 4 Department Of Oncology, Hôpital Fribourgois HFR, 1708 - Fribourg/CH
  • 5 Department Of Oncology/hematology, Cantonal Hospital St.Gallen, 9007 - St. gallen/CH
  • 6 Artment Of Medical Oncology And Hematology, Comprehensive Cancer Center Zurich, University Hospital Zurich, University of Zurich, 8091 - Zurich/CH
  • 7 Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne University, 1011 - Lausanne/CH
  • 8 Divison Of Oncology/hematology, Cantonal Hospital Graubünden, 7000 - Chur/CH
  • 9 Department Of Oncology, Inselspital Bern, Bern/CH
  • 10 Department Of Oncology/hematology, Cantonal Hospital Aarau, 5001 - Aarau/CH
  • 11 Department Of Oncology, Cantonal Hospital Baden, 5404 - Baden/CH
  • 12 Department Of Oncology, University Hospital Geneva, 1211 - Geneva/CH
  • 13 Department Of Thoracic Surgery, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne University, 1011 - Lausanne/CH
  • 14 Medical Oncology, Oncology Institute of Southern Switzerland IOSI, 6600 - Locarno/CH
  • 15 Department Of Oncology, Cantonal Hospital Winterthur, 8401 - Winterthur/CH
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1237MO

Background

For patients with resectable stage IIIA(N2) non-small cell lung cancer (NSCLC) neoadjuvant chemotherapy with 3 cycles cisplatin (cis)/docetaxel (doce) followed by surgery is an accepted standard of care achieving a 1-year event-free survival (EFS) of 48%. PD-(L)1 inhibitors have recently shown high response rates in resectable NSCLC.

Methods

Neoadjuvant treatment consisted of 3 cycles of cis 100 mg/m2 and doce 85 mg/m2 q3w followed by 2 cycles of durvalumab 750 mg q2w. Durvalumab was continued after surgery for 1 year. The primary endpoint is EFS at 1 year. The hypothesis for statistical considerations was an improvement of EFS at 1 year from 48% to 65%.

Results

Sixty-eight patients were included. Radiographic response rate was 44.8% (95%CI: 32.6-57.4) after neoadjuvant chemotherapy (CR: 4.5%, PR: 40.3%, SD: 44.8%) and 58.1% (95%CI: 44.8-70.5) after additional neoadjuvant immunotherapy (CR: 6.5%, PR: 51.6%, SD: 25.8%). Of the 55 resected patients, 10 patients (18.2%) had a pathological complete response and 33 patients (60.0%) a major pathological response defined as ≤10% viable tumor cells by central pathology review. Postoperative nodal down-staging was observed in 37 patients (67.3%). 1-year EFS was 73.3% (90%CI: 60.1-82.7). At the time of the analysis, median EFS was not reached. After a median follow up of 28 months, median OS was not reached. Thirteen patients had died with disease progression/disease recurrence as the most frequent reason (11 patients). 59 patients (88.1%) had an AE grade ≥3 including two fatal cases (one postoperative bleeding complication and one respiratory failure). Results for PD-L1 expression and tumor mutational burden will be presented during the meeting.

Conclusions

This is to our knowledge the largest study of patients with resectable stage IIIA(N2) NSCLC investigating perioperative immune checkpoint inhibitor therapy. The addition of perioperative durvalumab to standard of care cis/doce is safe and results in a encouraging 1-year EFS rate exceeding historical data of chemotherapy alone and achieves a high major pathological response rate.

Clinical trial identification

NCT02572843.

Editorial acknowledgement

Legal entity responsible for the study

Swiss Group for Clinical Cancer Research SAKK.

Funding

Foundation or academic group WITH funding from a pharma, biotech, or other commercial company - AstraZeneca.

Disclosure

S.I. Rothschild: Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Research grant/Funding (self): BMS; Advisory/Consultancy, Research grant/Funding (institution): Merck Serono; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Eisai; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: MSD; Advisory/Consultancy: Novartis; Honoraria (institution), Advisory/Consultancy: Roche; Advisory/Consultancy: Takeda. A. Zippelius: Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy: MSD; Advisory/Consultancy: BMS; Research grant/Funding (institution): Beyondsprings; Research grant/Funding (institution): Secarna; Research grant/Funding (institution): Crescendo. S. Savic Prince: Advisory/Consultancy: MSD; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Roche; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Thermo Fisher Scientific. D. Betticher: Advisory/Consultancy: MSD; Advisory/Consultancy: Roche; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Janssen-Cilag; Advisory/Consultancy: Novartis. M. Früh: Advisory/Consultancy: BMS; Advisory/Consultancy: MSD; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Roche; Advisory/Consultancy: Takeda. M. Joerger: Non-remunerated activity/ies: ESMO Press & Media Affairs Committee. C. Britschgi: Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Takeda; Advisory/Consultancy: Janssen-Cilag; Advisory/Consultancy: Boehringer Ingelheim. S. Peters: Advisory/Consultancy: AbbVie; Advisory/Consultancy: Amgen; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy: Bayer; Advisory/Consultancy: Biocartis; Advisory/Consultancy: Bioinvent; Advisory/Consultancy: Blueprint Medicines; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Boehringer Ingelheim; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): BMS; Advisory/Consultancy, Research grant/Funding (institution): Clovis; Advisory/Consultancy: Daiichi Sankyo; Advisory/Consultancy: Debiopharm; Honoraria (institution), Advisory/Consultancy: Eli Lilly; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): F. Hoffmann-La Roche; Advisory/Consultancy: Foundation Medicine; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Illumina; Advisory/Consultancy: Janssen; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): MSD; Advisory/Consultancy, Research grant/Funding (institution): Merck Serono; Advisory/Consultancy: Merrimack; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy: Pharma Mar; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Advisory/Consultancy: Regeneron; Honoraria (institution), Advisory/Consultancy: Sanofi; Advisory/Consultancy: Seattle Genetics; Honoraria (institution), Advisory/Consultancy: Takeda; Advisory/Consultancy: Vaccibody; Research grant/Funding (institution): Amgen; Research grant/Funding (institution): Biodesix. M.T. Mark: Advisory/Consultancy: BMS; Advisory/Consultancy: Roche; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy: MSD; Advisory/Consultancy: Takeda. W. Janthur: Honoraria (self), Advisory/Consultancy: Roche; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Takeda; Honoraria (self), Advisory/Consultancy: MSD; Advisory/Consultancy: Novartis. P.R. Froesch: Advisory/Consultancy: Roche; Advisory/Consultancy: Takeda; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: BMS; Advisory/Consultancy: Pfizer. M. Pless: Advisory/Consultancy: Abbvie; Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer Ingelheim; Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Advisory/Consultancy: Eisai; Advisory/Consultancy: MSD; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Roche; Advisory/Consultancy: Takeda; Advisory/Consultancy: MSD; Travel/Accommodation/Expenses: Vifor; Honoraria (institution): Janssen-Cilag.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings